225 related articles for article (PubMed ID: 25855582)
61. Biomarkers for the early diagnosis of hepatocellular carcinoma.
Tsuchiya N; Sawada Y; Endo I; Saito K; Uemura Y; Nakatsura T
World J Gastroenterol; 2015 Oct; 21(37):10573-83. PubMed ID: 26457017
[TBL] [Abstract][Full Text] [Related]
62. [Clinical evaluation of PIVKA-II as a marker of hepatocellular carcinoma].
Arima K; Kodama T; Suga M; Sakamoto H; Ohe Y; Yachi A
Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 2):3049-52. PubMed ID: 2476968
[TBL] [Abstract][Full Text] [Related]
63. Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease.
Zinkin NT; Grall F; Bhaskar K; Otu HH; Spentzos D; Kalmowitz B; Wells M; Guerrero M; Asara JM; Libermann TA; Afdhal NH
Clin Cancer Res; 2008 Jan; 14(2):470-7. PubMed ID: 18223221
[TBL] [Abstract][Full Text] [Related]
64. [Usefulness of serum alpha-fetoprotein (AFP) as a marker for hepatocellular carcinoma (HCC) in hepatitis C virus related cirrhosis: analysis of the factors influencing AFP elevation without HCC development].
Kim KA; Lee JS; Jung ES; Kim JY; Bae WK; Kim NH; Moon YS
Korean J Gastroenterol; 2006 Nov; 48(5):321-6. PubMed ID: 17132920
[TBL] [Abstract][Full Text] [Related]
65. Circulating microRNAs as biomarkers for diagnosis of early hepatocellular carcinoma associated with hepatitis B virus.
Hung CH; Hu TH; Lu SN; Kuo FY; Chen CH; Wang JH; Huang CM; Lee CM; Lin CY; Yen YH; Chiu YC
Int J Cancer; 2016 Feb; 138(3):714-20. PubMed ID: 26264553
[TBL] [Abstract][Full Text] [Related]
66. Prognostic and diagnostic value of des-γ-carboxy prothrombin in liver cancer.
Bertino G; Ardiri AM; Calvagno GS; Bertino N; Boemi PM
Drug News Perspect; 2010 Oct; 23(8):498-508. PubMed ID: 21031166
[TBL] [Abstract][Full Text] [Related]
67. Serum des-gamma-carboxy prothrombin levels determined by a new generation of sensitive immunoassays in patients with small-sized hepatocellular carcinoma.
Nomura F; Ishijima M; Kuwa K; Tanaka N; Nakai T; Ohnishi K
Am J Gastroenterol; 1999 Mar; 94(3):650-4. PubMed ID: 10086646
[TBL] [Abstract][Full Text] [Related]
68. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.
Durazo FA; Blatt LM; Corey WG; Lin JH; Han S; Saab S; Busuttil RW; Tong MJ
J Gastroenterol Hepatol; 2008 Oct; 23(10):1541-8. PubMed ID: 18422961
[TBL] [Abstract][Full Text] [Related]
69. Evaluation of the diagnostic accuracy of des-gamma-carboxy prothrombin and alpha-fetoprotein alone or in combination for hepatocellular carcinoma: A systematic review and meta-analysis.
Fan J; Chen Y; Zhang D; Yao J; Zhao Z; Jiang Y; Li Y; Guo Y
Surg Oncol; 2020 Sep; 34():245-255. PubMed ID: 32891338
[No Abstract] [Full Text] [Related]
70. Multi-marker diagnosis method for early Hepatocellular Carcinoma based on surface plasmon resonance.
Yu H; Han R; Su J; Chen H; Li D
Clin Chim Acta; 2020 Mar; 502():9-14. PubMed ID: 31837298
[TBL] [Abstract][Full Text] [Related]
71. [Biomarkers for neoplasmas in digestive organs].
Iwasaki Y; Arai K; Katayanagi S; Takahashi K; Yamaguchi T; Matsumoto H; Miyamoto H
Gan To Kagaku Ryoho; 2004 Jul; 31(7):1015-20. PubMed ID: 15272578
[TBL] [Abstract][Full Text] [Related]
72. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review.
Colli A; Fraquelli M; Casazza G; Massironi S; Colucci A; Conte D; Duca P
Am J Gastroenterol; 2006 Mar; 101(3):513-23. PubMed ID: 16542288
[TBL] [Abstract][Full Text] [Related]
73. Des-gamma-carboxyprothrombin in hepatocellular carcinoma after vitamin K1 injection.
Buffet C; Bismuth E; Hagege H; Etienne JP
Dig Dis Sci; 1989 Jun; 34(6):963-4. PubMed ID: 2470560
[No Abstract] [Full Text] [Related]
74. Analytical and Clinical Performance Evaluation of the Abbott Architect PIVKA Assay.
Ko DH; Hyun J; Kim HS; Park MJ; Kim JS; Park JY; Shin DH; Cho HC
Ann Clin Lab Sci; 2018 Jan; 48(1):75-80. PubMed ID: 29531000
[TBL] [Abstract][Full Text] [Related]
75. Current and Emerging Tools for Hepatocellular Carcinoma Surveillance.
Adeniji N; Dhanasekaran R
Hepatol Commun; 2021 Dec; 5(12):1972-1986. PubMed ID: 34533885
[TBL] [Abstract][Full Text] [Related]
76. Magnetic-bioluminescent-nanoliposomes for ultrasensitive and portable detection of protein biomarkers in blood.
Liu P; Fang X; Cao H; Gu M; Kong J; Deng A
Anal Chim Acta; 2018 Dec; 1039():98-107. PubMed ID: 30322558
[TBL] [Abstract][Full Text] [Related]
77. [Research progress of serum biomarkers for early screening of hepatocellular carcinoma].
Zhu W; Huang Y
Zhonghua Gan Zang Bing Za Zhi; 2021 Apr; 29(4):308-312. PubMed ID: 33979955
[TBL] [Abstract][Full Text] [Related]
78. Simply and sensitively simultaneous detection hepatocellular carcinoma markers AFP and miRNA-122 by a label-free resonance light scattering sensor.
Chen F; Zhang F; Liu Y; Cai C
Talanta; 2018 Aug; 186():473-480. PubMed ID: 29784390
[TBL] [Abstract][Full Text] [Related]
79. Raman based hepatocellular carcinoma biomarker detection.
Santiago-Cordoba MA; Romano PR; MacKay A; Demirel MC
Annu Int Conf IEEE Eng Med Biol Soc; 2011; 2011():3672-5. PubMed ID: 22255136
[TBL] [Abstract][Full Text] [Related]
80. MicroRNAs as biomarkers for hepatocellular carcinoma: a diagnostic meta-analysis.
Hu QY; Jiang H; Su J; Jia YQ
Clin Lab; 2013; 59(9-10):1113-20. PubMed ID: 24273935
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
